Edoxaban and Rifampicin: Drug Interaction Guide

Quick answer: This is a major interaction — avoid combining Edoxaban and Rifampicin unless specifically directed by your doctor.

Interaction severity: Major — avoid combination

How Edoxaban interacts with Rifampicin

Rifampicin induces CYP3A4 and P-glycoprotein, reducing edoxaban plasma concentrations and potentially leading to thromboembolic events.

What you should do

Avoid concurrent use; if combination is unavoidable, consider switching to a vitamin K antagonist with INR monitoring.

Key facts

Severity

Major — avoid combination

Mechanism

Rifampicin induces CYP3A4 and P-glycoprotein, reducing edoxaban plasma concentrations and potentially leading to thrombo...

Action

Avoid concurrent use; if combination is unavoidable, consider switching to a vitamin K antagonist with INR monitoring.

Important medical disclaimer: This page provides educational information about drug interactions for general reference. It is not a substitute for professional medical advice, diagnosis, or treatment. Always discuss your specific medications with a qualified healthcare provider before starting, stopping, or changing any treatment. About our editorial team.

Frequently asked questions

Can I take Edoxaban and Rifampicin together?

No — this combination should generally be avoided. Avoid concurrent use; if combination is unavoidable, consider switching to a vitamin K antagonist with INR monitoring.

What is the severity of this interaction?

The interaction between Edoxaban and Rifampicin is classified as Major — avoid combination. Rifampicin induces CYP3A4 and P-glycoprotein, reducing edoxaban plasma concentrations and potentially leading to thromboembolic events.

What should I do if I'm prescribed both?

Avoid concurrent use; if combination is unavoidable, consider switching to a vitamin K antagonist with INR monitoring. Always consult your prescribing clinician — do not stop or change medications without medical guidance.

Last reviewed: by iMedic Medical Editorial Team. Our editorial process.